Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Biophytis SA ( (FR:ALBPS) ) has shared an update.
Biophytis SA announced its participation in the 15th International Conference on Frailty and Sarcopenia Research, where it will present preliminary data on BIO101 for treating obesity-associated sarcopenia. This participation underscores Biophytis’s commitment to advancing treatments for age-related diseases and highlights its role in the scientific community focused on frailty and sarcopenia.
More about Biophytis SA
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. Their lead drug candidate, BIO101, is being developed for muscular diseases, respiratory diseases, and metabolic disorders. The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. Biophytis is listed on Euronext Growth Paris and the OTC market.
YTD Price Performance: -14.57%
Average Trading Volume: 7,225
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €4.61M
See more insights into ALBPS stock on TipRanks’ Stock Analysis page.